Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novavax Plays Down EU COVID Vaccine Contract Delay

Manufacturing Issues Not To Blame

Executive Summary

Investors are anxious about the delay to Novavax’s deal with the EU, and want to know how and when it might file the vaccine with regulators.

You may also be interested in...



UK Government Plays Matchmaker In GSK/Novavax Deal To ‘Onshore’ COVID-19 Vaccine Production

The UK wants to consolidate its rapid vaccine roll-out and its domestic supply chain via the alliance

EU Tightens Criteria For Allowing COVID-19 Vaccine Exports

As the coronavirus crisis continues to worsen across Europe, the EU authorities have come up with a new way of determining whether exports of coronavirus vaccines should be allowed.

Coronavirus Update: Novavax Vaccine Shows High Effectiveness Against Variants

The vaccine is 95.6% effective at preventing infection with the original COVID-19 strain and 85.6% effective at protecting against the B.1.1.7 strain, with an overall level of protection across the strains of 89.3%. Meanwhile, South Korea has drawn up a national vaccination plan and AstraZeneca is set to produce doses of its vaccine in Japan.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144074

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel